Integra, Inc.

Mumbai: Jenny was there, and so was Justin. Also, Ranveer, Hrithik, Madhuri, Karan and Don Junior. If anyone hasn’t heard of Raj Ramalinga Mantena by now, they’ve been living under the proverbial rock. Over the past few days, the lavish wedding celebrations of the US-based billionaire pharmaceutical entrepreneur ’s daughter in Udaipur have set social media alight. Mantena ’s daughter Netra is tying the knot with Vamsi Gadiraju, a technology entrepreneur who cofounded startup Superorder in the US. For those not familiar with first names, attendees and performers included Jennifer Lopez , Justin Bieber , Ranveer Singh, Hrithik Roshan, Varun Dhavan, Kriti Sanon, Madhuri Dixit and Karan Johar. Donald Trump Jr was there too. But who is Raj Mantena and how did the world miss his meteoric rise? The reclusive, Florida-based Indian-born businessman has been little known outside a circle of close friends in Hyderabad’s pharmaceutical hub. Not anymore, it would seem. ET spoke to people who know him closely to put together a picture of the man who’s behind this latest and most astonishing of spectacles that rivals some other recent nuptial jamborees. Foreseeing the Future “Raju has a king-size taste for luxury. His home at Manalapan (Florida) has a car museum, and the basement has a bar only the elite can think of,” a person told ET. Mantena , a serial healthcare entrepreneur, moved to the US after studying computer science in India, before taking up a pharmacy degree there. His wealth—said to be in billions of dollars—comes from the intersection of these two diverse fields of science that have complemented each other over time. Early breakthroughs in the field of medicine, particularly cancer treatments, the use of digital technology in healthcare services, and rapid changes in reimbursement patterns in the US fuelled Mantena ’s entrepreneurial vision. He entered businesses, scaled them to a size and sold them to large corporations at rich valuations. From cloud-based healthcare solutions for precision medicine through Integra Connect to selling low-priced generic drugs as part of Ingenus Pharmaceuticals, Mantena’s businesses continue to boom. Integra Connect says it’s a value-based precision medicine company that turns real-world data into deep insights in cancer treatment. As part of the oncology care model, Integra says it generated $260 million in value-based care revenue and over $100 million in shared savings for participating companies. OncoScripts, an oncology-focused pharmacy founded by Mantena in the 90s, was later acquired by a subsidiary of pharma distribution heavyweight Cardinal Health. Next, Mantena built International Oncology Network, a group purchasing and oncology community network that was acquired by AmerisourceBergen, now Cencora, in 2001. He then founded ICORE Healthcare, a provider of healthcare plans to manage cost trends in specialty drugs, selling the venture to Magellan Health Services in 2006 for more than $200 million. Home Ties While the businesses thrived in the US, back home in India, Mantena extended his connections deeper into Andhra Pradesh political circles. “The Mantena family is related to the Gokaraju family,” which carries political heft in Andhra Pradesh, said a person in Hyderabad. Several top executives in the US and in the Indian pharmaceutical industry said they hadn’t heard much about the man. “At an international conference on precision medicine in Orlando recently, I do not remember seeing a representative from Integra Connect,” said a senior business development executive in the field of oncology. Similar notes came from another biotech entrepreneur, based in San Francisco for over three decades. A November 13 release from Ingenus showed the company secured approval from the US Food and Drug Administration (FDA) for the only generic equivalent of Premarin, a tablet used for treating osteoporosis and a few effects of menopause. Mantena’s profile on LinkedIn shows only a few connections and it is learnt that he uses the networking site sparingly. Still, the extravagant festivities in Udaipur will ensure the name won’t be easily forgotten. By Vikas Dandekar ,

动脉网获悉，近日，广东东纳私募基金管理有限公司（以下简称“东纳投资”）完成对广州见微医疗科技有限公司（以下简称“见微医疗”）的数千万股权投资。此次投资标志着东纳投资在神经外科高值医疗器械领域的进一步深化布局，也彰显了市场对见微医疗技术实力与发展前景的高度认可。 01 机构介绍：东纳投资——深耕产业，赋能成长 广东东纳私募基金管理有限公司成立于2023年，由资深投资人士和产业人士共同发起设立，发起股东均来自华南及华东知名机构的投资合伙人、多家国内上市公司主要股东和高管，大型金融机构高管、领先的数字信息化企业创始人等精英人士组成，核心管理团队深耕投融资领域十五年以上，在业内拥有良好声誉，具备严谨高效的投资能力和丰富的资源整合能力。 东纳医健基金重点关注填补医学空白和改变传统医疗手段的技术创新领域，包括国产替代的创新器械、细胞治疗相关再生医学、慢病医疗及退行性疾病、以及AI医药创新等领域。基金参与方包括政府基金和数家上市公司，基金管理人逐步搭建了进院（三甲以及基层医药）-OTC-线上销售-产品出海的产业资源，为投前和投后企业在临床需求判断、市场销售和战略布局方面提供直接支持。基金管理人同时在前沿技术孵化、加快研发周期、销售渠道、融资及并购层面，为投后企业提供全方位赋能。 02 项目介绍：脑脊液管理整体解决方案的引领者 见微医疗成立于2023年4月，是一家专注于脑科学领域创新医疗器械的研发型企业，致力于打造国内首个脑脊液管理整体解决方案，并同步布局新型液态介入栓塞剂等前沿产品。公司核心产品管线覆盖颅内压监护系统、亲水涂层/含药颅脑外引流系统、可调压分流管等，旨在为脑部疾病的诊断与治疗提供更智能、精准、安全的器械支持。 公司依托有源设备、材料技术、传感平台三大技术平台，构建了完整的自主研发体系。目前，其亲水涂层颅脑外引流管已获批上市，颅内压监护系统、含药外引流管、可调压分流管等核心产品也将在2026–2027年陆续获证。 03 项目亮点：技术领先、团队资深、资源协同 ■ 技术平台具备国产替代与国际化的双重潜力 见微医疗在生物传感器封装、载药缓释、高分子材料合成等核心技术上实现突破，多项产品有望成为“国产首证”；产品性能媲美进口品牌（如Integra、美敦力），且具备智能化、多规格、低成本等优势；已启动FDA注册申请，具备出海基础。 ■ 核心团队源自上市公司，具备产业化与商业化经验 核心团队在神经外科高值耗材的研发、注册、生产与市场方面具备多年实战经验。公司实控人在医疗器械领域的战略视野与资源整合能力为见微医疗的发展提供了强大支撑。 ■ 渠道协同明确，销售路径清晰   见微医疗已与上市公司签署全球独家代理协议，由后者负责产品市场推广与销售。上市公司拥有覆盖全国超1700家医院及近90个国家和地区的成熟渠道网络，为见微产品快速放量提供了保障。 04 赛道处于高速成长期，国产替代空间巨大 中国颅内压监测市场年增速超20%，2025年规模预计达15亿元，当前渗透率仅11%，远低于海外（36%-55%）；脑脊液外引流系统年增速约10%，特殊涂层、含药导管等高附加值产品占比提升，国产企业刚起步；可调压分流管、液态栓塞剂等细分领域仍由外资垄断，国产企业具备“首证+成本+渠道”三重优势。 05 结语 东纳投资此次对见微医疗的战略投资，不仅是对其技术实力与团队背景的认可，更是对中国神经外科器械国产化趋势的坚定看好。未来，东纳将持续助力见微医疗推进产品研发与推广，加速其在中国乃至全球市场的商业化进程，共同推动中国脑科学医疗器械的创新发展与进口替代。 如果您想对接文章中提到的项目，或您的项目想被动脉网报道，或者发布融资新闻，请与我们联系；也可加入动脉网行业社群，结交更多志同道合的好友。 近 期 推 荐 声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。文中如果涉及企业信息和数据，均由受访者向分析师提供并确认。 动脉网，未来医疗服务平台

FORT LAUDERDALE, Fla., Oct. 15, 2025 /PRNewswire/ -- As legacy spine and orthopedic companies divest from their core device portfolios and retreat from innovation, Harvard-trained orthopedic spine surgeon and CEO Dr. Kingsley R. Chin has demonstrated consistent leadership in guiding KIC Ventures to advance a bold new vision — building sustainable global markets in outpatient interventional spine surgery, regenerative biologics, and motion-preserving viscoelastic disc replacements. Continue Reading Dr. Kingsley R. Chin teaching fellow physicians at KIC Ventures headquarters in Florida—sharing his expertise in Less Exposure Spine Surgery (LESS™) and empowering the next generation of physician innovators. KIC Ventures is defined by its physician-led model, featuring Chief Medical Officer Dr. Erik Spayde, a Harvard-trained orthopedic spine surgeon, and Chief Technology Officer Vito Lore, who has worked alongside Dr. Chin for over 15 years driving innovation in Less Exposure Spine Surgery (LESS) technologies. Supported by a seasoned executive team and a network of physician investors — many participating through self-directed IRAs (SDIRAs) via the IRA Club — KIC Ventures continues to lead where others have retreated. The past decade has marked a wave of spine industry divestitures, as traditional giants exit innovation-heavy markets to consolidate and protect profits: NuVasive, the leader in lateral interbody cage fusion, was assimilated into Globus and effectively exited as an independent spine innovator. Biomet was acquired by Zimmer, which later divested its spine business into ZimVie, and then ZimVie was sold to Highbridge — completing a full exit from spine. Stryker divested Stryker Spine, walking away from decades of development. Integra divested SeaSpine, another exit from spine. Aesculap divested its ActivL articulating disc replacement program. DePuy Synthes divested its ProDisc articulating disc replacement. Orthofix divested its M6 disc replacement after widespread osteolysis concerns. These moves follow the Vertiflex recall by Boston Scientific and broader orthopedic restructuring at Johnson & Johnson, signaling a systemic withdrawal from the innovation-intensive spine sector. "While others are exiting spine, we're expanding it," said Dr. Kingsley R. Chin, CEO and Founder of KIC Ventures. "We see what's coming next — a shift to regenerative, motion-preserving, and outpatient treatments. Innovation doesn't disappear; it migrates to those willing to lead." AxioMed Viscoelastic Disc Replacement The only total disc replacement to complete a U.S. IDE study with over 10 years of published outcomes, AxioMed restores natural disc motion instead of eliminating it. Global commercialization is planned for 2026, marking the new standard for motion preservation in spine. NanoFuse Biologics Combining synthetic 45S5 Bioactive Glass with demineralized bone matrix (DBM), NanoFuse delivers a regenerative therapeutic platform with a five-year shelf life. KIC Ventures is extending NanoFuse's capabilities beyond bone regeneration into therapeutic biologic applications, positioning it as a next-generation regenerative medicine solution. ELID (Endoscopic Lumbar Intralaminar Decompression) ELID represents a breakthrough in endoscopic decompression, enabling targeted intralaminar distraction and decompression for both spine surgeons and interventional pain specialists. Paired with NANISX's LESS Exposure Spine Surgery (LESS) portfolio — InSpan, FacetFuse, and Sacrix — ELID anchors a new interventional outpatient market, moving spine surgery from the hospital to physician-owned ambulatory centers. "Cardiology evolved by shifting from open-heart surgery to interventional cardiology," said Dr. Chin. "Spine is undergoing the same transformation. The future belongs to physician-led outpatient care — earlier treatment, preserved anatomy, and faster recovery. This is how real innovation scales." Dr. Erik Spayde, CMO and Harvard-trained orthopedic spine surgeon, highlighted the physician-led foundation: "Our clinical insight drives our innovation. We know where the bottlenecks are because we've lived them. That's why our solutions are practical, evidence-based, and built to last." Vito Lore, CTO, reinforced KIC Ventures' product philosophy: "Our innovation strategy is guided by our LESS treatment philosophy — Less Exposure Spine Surgery. We build best-in-class technologies that deliver superior outcomes with less trauma, less cost, and less complexity." Aditya Humad, President and CFO, emphasized the company's physician-investor model: "Our investors are doctors who understand the clinical and economic value of what we're building. Through partnerships with the IRA Club, many have invested using tax-free retirement capital via SDIRAs — turning their savings into ownership in the future of spine." Every KIC Ventures technology is supported by peer-reviewed research published in top spine and orthopedic journals. Through the LESS Society VET Tour, KIC Ventures and its physician faculty are training surgeons globally to achieve standardized competency in interventional and outpatient spine techniques. Join us and invest. Visit the website: or call us at +1(855)411-LESS KIC Ventures is a physician-founded private equity healthtech group driving innovation in spine and orthopedics. Guided by the REP principles — Restore Function, Early Intervention, Preserve Anatomy, KIC Ventures acquires, develops, and commercializes technologies that transition spine care from hospital-based fusion to regenerative, motion-preserving, and outpatient solutions. The KIC Ventures portfolio includes AxioMed, NanoFuse Biologics, and NANISX, each advancing the next generation of Interventional Spine Surgery and Regenerative Therapeutics worldwide. SOURCE KIC Ventures WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED